nodes	percent_of_prediction	percent_of_DWPC	metapath
Pasireotide—Desmopressin—PTGS2—muscle cancer	0.0568	1	CrCbGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—TP73—muscle cancer	0.0482	0.078	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—TP73—muscle cancer	0.0394	0.0638	CbGpPWpGaD
Pasireotide—SSTR2—GPCRs, Other—CNR1—muscle cancer	0.033	0.0534	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—CNR1—muscle cancer	0.0197	0.0319	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—CNR1—muscle cancer	0.0189	0.0306	CbGpPWpGaD
Pasireotide—SSTR3—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.0183	0.0296	CbGpPWpGaD
Pasireotide—SSTR1—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.0175	0.0284	CbGpPWpGaD
Pasireotide—SSTR5—G alpha (i) signalling events—CNR1—muscle cancer	0.0168	0.0271	CbGpPWpGaD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.0157	0.0253	CbGpPWpGaD
Pasireotide—SSTR5—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.0155	0.0252	CbGpPWpGaD
Pasireotide—SSTR2—G alpha (i) signalling events—CNR1—muscle cancer	0.0155	0.025	CbGpPWpGaD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.015	0.0243	CbGpPWpGaD
Pasireotide—SSTR2—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.0143	0.0232	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—PTCH1—muscle cancer	0.0141	0.0229	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—PTCH1—muscle cancer	0.0135	0.0219	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.0133	0.0215	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.0123	0.0199	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—PTCH1—muscle cancer	0.012	0.0194	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—CNR1—muscle cancer	0.0119	0.0193	CbGpPWpGaD
Pasireotide—Prothrombin level increased—Doxorubicin—muscle cancer	0.0115	0.0353	CcSEcCtD
Pasireotide—SSTR1—GPCR ligand binding—CNR1—muscle cancer	0.0114	0.0185	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—PTCH1—muscle cancer	0.0111	0.0179	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—KIDINS220—muscle cancer	0.0109	0.0176	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—KIDINS220—muscle cancer	0.0104	0.0169	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—CNR1—muscle cancer	0.0101	0.0164	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—CNR1—muscle cancer	0.00936	0.0151	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—KIDINS220—muscle cancer	0.00925	0.015	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.00899	0.0145	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—KIDINS220—muscle cancer	0.00854	0.0138	CbGpPWpGaD
Pasireotide—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00819	0.0252	CcSEcCtD
Pasireotide—Pain in extremity—Vincristine—muscle cancer	0.00813	0.025	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.00736	0.0119	CbGpPWpGaD
Pasireotide—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00732	0.0225	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—PTCH1—muscle cancer	0.00725	0.0117	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—PTCH1—muscle cancer	0.00695	0.0112	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—CNR1—muscle cancer	0.00674	0.0109	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—CNR1—muscle cancer	0.00646	0.0105	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—PTCH1—muscle cancer	0.00617	0.00998	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—CNR1—muscle cancer	0.00612	0.0099	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—CNR1—muscle cancer	0.00587	0.00949	CbGpPWpGaD
Pasireotide—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00581	0.0179	CcSEcCtD
Pasireotide—SSTR5—GPCR downstream signaling—CNR1—muscle cancer	0.00573	0.00927	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—PTCH1—muscle cancer	0.00569	0.00921	CbGpPWpGaD
Pasireotide—Alopecia—Dactinomycin—muscle cancer	0.00556	0.0171	CcSEcCtD
Pasireotide—SSTR2—GPCR downstream signaling—CNR1—muscle cancer	0.00529	0.00856	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CNR1—muscle cancer	0.00521	0.00842	CbGpPWpGaD
Pasireotide—Anaemia—Dactinomycin—muscle cancer	0.00506	0.0156	CcSEcCtD
Pasireotide—Alopecia—Vincristine—muscle cancer	0.00497	0.0153	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—CNR1—muscle cancer	0.0048	0.00777	CbGpPWpGaD
Pasireotide—Back pain—Vincristine—muscle cancer	0.00474	0.0146	CcSEcCtD
Pasireotide—Injection site reaction—Doxorubicin—muscle cancer	0.00468	0.0144	CcSEcCtD
Pasireotide—Myalgia—Dactinomycin—muscle cancer	0.00466	0.0143	CcSEcCtD
Pasireotide—Diabetes mellitus—Methotrexate—muscle cancer	0.00453	0.0139	CcSEcCtD
Pasireotide—Anaemia—Vincristine—muscle cancer	0.00452	0.0139	CcSEcCtD
Pasireotide—Vertigo—Vincristine—muscle cancer	0.0044	0.0135	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—PTCH1—muscle cancer	0.00428	0.00693	CbGpPWpGaD
Pasireotide—Hypertension—Vincristine—muscle cancer	0.00423	0.013	CcSEcCtD
Pasireotide—Myalgia—Vincristine—muscle cancer	0.00417	0.0128	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—PTCH1—muscle cancer	0.00411	0.00665	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00407	0.0125	CcSEcCtD
Pasireotide—Alopecia—Etoposide—muscle cancer	0.00403	0.0124	CcSEcCtD
Pasireotide—Diabetes mellitus—Doxorubicin—muscle cancer	0.00393	0.0121	CcSEcCtD
Pasireotide—Decreased appetite—Dactinomycin—muscle cancer	0.00389	0.012	CcSEcCtD
Pasireotide—Fatigue—Dactinomycin—muscle cancer	0.00386	0.0119	CcSEcCtD
Pasireotide—Back pain—Etoposide—muscle cancer	0.00384	0.0118	CcSEcCtD
Pasireotide—Hypotension—Vincristine—muscle cancer	0.00373	0.0115	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—FOXO4—muscle cancer	0.00368	0.00596	CbGpPWpGaD
Pasireotide—Anaemia—Etoposide—muscle cancer	0.00367	0.0113	CcSEcCtD
Pasireotide—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00366	0.0112	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—PTCH1—muscle cancer	0.00364	0.00589	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00364	0.0112	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—CNR1—muscle cancer	0.00362	0.00585	CbGpPWpGaD
Pasireotide—Insomnia—Vincristine—muscle cancer	0.00361	0.0111	CcSEcCtD
Pasireotide—Vertigo—Etoposide—muscle cancer	0.00356	0.011	CcSEcCtD
Pasireotide—Abdominal pain—Dactinomycin—muscle cancer	0.00353	0.0109	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—FOXO4—muscle cancer	0.00353	0.00571	CbGpPWpGaD
Pasireotide—Hypoglycaemia—Doxorubicin—muscle cancer	0.0035	0.0108	CcSEcCtD
Pasireotide—Decreased appetite—Vincristine—muscle cancer	0.00347	0.0107	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—CNR1—muscle cancer	0.00347	0.00561	CbGpPWpGaD
Pasireotide—Fatigue—Vincristine—muscle cancer	0.00344	0.0106	CcSEcCtD
Pasireotide—Hypertension—Etoposide—muscle cancer	0.00342	0.0105	CcSEcCtD
Pasireotide—Constipation—Vincristine—muscle cancer	0.00342	0.0105	CcSEcCtD
Pasireotide—Pain in extremity—Doxorubicin—muscle cancer	0.00342	0.0105	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—PTCH1—muscle cancer	0.00336	0.00544	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Vincristine—muscle cancer	0.00327	0.01	CcSEcCtD
Pasireotide—Asthenia—Dactinomycin—muscle cancer	0.00321	0.00987	CcSEcCtD
Pasireotide—Abdominal pain—Vincristine—muscle cancer	0.00316	0.00971	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—FOXO4—muscle cancer	0.00313	0.00507	CbGpPWpGaD
Pasireotide—Dry skin—Doxorubicin—muscle cancer	0.00313	0.00963	CcSEcCtD
Pasireotide—Abdominal pain upper—Doxorubicin—muscle cancer	0.00312	0.00959	CcSEcCtD
Pasireotide—Hypokalaemia—Doxorubicin—muscle cancer	0.00311	0.00956	CcSEcCtD
Pasireotide—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.00308	0.00946	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—CNR1—muscle cancer	0.00307	0.00497	CbGpPWpGaD
Pasireotide—Diarrhoea—Dactinomycin—muscle cancer	0.00306	0.00941	CcSEcCtD
Pasireotide—Nasopharyngitis—Doxorubicin—muscle cancer	0.00305	0.00939	CcSEcCtD
Pasireotide—Hypotension—Etoposide—muscle cancer	0.00302	0.0093	CcSEcCtD
Pasireotide—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00301	0.00927	CcSEcCtD
Pasireotide—Abdominal distension—Doxorubicin—muscle cancer	0.00297	0.00914	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—IGF2—muscle cancer	0.00296	0.00478	CbGpPWpGaD
Pasireotide—Influenza—Doxorubicin—muscle cancer	0.00295	0.00908	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—FOXO4—muscle cancer	0.00289	0.00468	CbGpPWpGaD
Pasireotide—Asthenia—Vincristine—muscle cancer	0.00287	0.00882	CcSEcCtD
Pasireotide—Vomiting—Dactinomycin—muscle cancer	0.00284	0.00875	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—CNR1—muscle cancer	0.00284	0.00459	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—IGF2—muscle cancer	0.00283	0.00459	CbGpPWpGaD
Pasireotide—Decreased appetite—Etoposide—muscle cancer	0.00281	0.00865	CcSEcCtD
Pasireotide—Fatigue—Etoposide—muscle cancer	0.00279	0.00858	CcSEcCtD
Pasireotide—Constipation—Etoposide—muscle cancer	0.00277	0.00851	CcSEcCtD
Pasireotide—Diarrhoea—Vincristine—muscle cancer	0.00273	0.00841	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—FOXO1—muscle cancer	0.00272	0.0044	CbGpPWpGaD
Pasireotide—Hyperglycaemia—Doxorubicin—muscle cancer	0.00266	0.00819	CcSEcCtD
Pasireotide—Nausea—Dactinomycin—muscle cancer	0.00266	0.00817	CcSEcCtD
Pasireotide—Gastrointestinal pain—Etoposide—muscle cancer	0.00265	0.00814	CcSEcCtD
Pasireotide—Dizziness—Vincristine—muscle cancer	0.00264	0.00813	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—FOXO1—muscle cancer	0.00261	0.00422	CbGpPWpGaD
Pasireotide—Abdominal pain—Etoposide—muscle cancer	0.00256	0.00787	CcSEcCtD
Pasireotide—Vomiting—Vincristine—muscle cancer	0.00254	0.00781	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—IGF2—muscle cancer	0.00251	0.00407	CbGpPWpGaD
Pasireotide—Headache—Vincristine—muscle cancer	0.0025	0.0077	CcSEcCtD
Pasireotide—Alopecia—Methotrexate—muscle cancer	0.00241	0.00742	CcSEcCtD
Pasireotide—Nausea—Vincristine—muscle cancer	0.00237	0.0073	CcSEcCtD
Pasireotide—Oedema peripheral—Doxorubicin—muscle cancer	0.00233	0.00716	CcSEcCtD
Pasireotide—Asthenia—Etoposide—muscle cancer	0.00232	0.00714	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—IGF2—muscle cancer	0.00232	0.00375	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—FOXO1—muscle cancer	0.00231	0.00374	CbGpPWpGaD
Pasireotide—Back pain—Methotrexate—muscle cancer	0.0023	0.00707	CcSEcCtD
Pasireotide—Pruritus—Etoposide—muscle cancer	0.00229	0.00704	CcSEcCtD
Pasireotide—Diarrhoea—Etoposide—muscle cancer	0.00221	0.00681	CcSEcCtD
Pasireotide—Anaemia—Methotrexate—muscle cancer	0.0022	0.00675	CcSEcCtD
Pasireotide—Dizziness—Etoposide—muscle cancer	0.00214	0.00658	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—FOXO1—muscle cancer	0.00214	0.00345	CbGpPWpGaD
Pasireotide—Vertigo—Methotrexate—muscle cancer	0.00213	0.00656	CcSEcCtD
Pasireotide—Alopecia—Doxorubicin—muscle cancer	0.00209	0.00642	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—KIT—muscle cancer	0.00207	0.00335	CbGpPWpGaD
Pasireotide—Vomiting—Etoposide—muscle cancer	0.00206	0.00633	CcSEcCtD
Pasireotide—Headache—Etoposide—muscle cancer	0.00203	0.00624	CcSEcCtD
Pasireotide—Myalgia—Methotrexate—muscle cancer	0.00202	0.00622	CcSEcCtD
Pasireotide—Arthralgia—Methotrexate—muscle cancer	0.00202	0.00622	CcSEcCtD
Pasireotide—Back pain—Doxorubicin—muscle cancer	0.00199	0.00612	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—KIT—muscle cancer	0.00199	0.00322	CbGpPWpGaD
Pasireotide—Nausea—Etoposide—muscle cancer	0.00192	0.00591	CcSEcCtD
Pasireotide—Anaemia—Doxorubicin—muscle cancer	0.0019	0.00585	CcSEcCtD
Pasireotide—Vertigo—Doxorubicin—muscle cancer	0.00185	0.00568	CcSEcCtD
Pasireotide—Hypotension—Methotrexate—muscle cancer	0.00181	0.00557	CcSEcCtD
Pasireotide—Hypertension—Doxorubicin—muscle cancer	0.00178	0.00546	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00177	0.00543	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—KIT—muscle cancer	0.00176	0.00285	CbGpPWpGaD
Pasireotide—Insomnia—Methotrexate—muscle cancer	0.00175	0.00539	CcSEcCtD
Pasireotide—Myalgia—Doxorubicin—muscle cancer	0.00175	0.00539	CcSEcCtD
Pasireotide—Arthralgia—Doxorubicin—muscle cancer	0.00175	0.00539	CcSEcCtD
Pasireotide—Anxiety—Doxorubicin—muscle cancer	0.00174	0.00537	CcSEcCtD
Pasireotide—Decreased appetite—Methotrexate—muscle cancer	0.00169	0.00518	CcSEcCtD
Pasireotide—Fatigue—Methotrexate—muscle cancer	0.00167	0.00514	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—MDM2—muscle cancer	0.00163	0.00264	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—KIT—muscle cancer	0.00163	0.00263	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Methotrexate—muscle cancer	0.00159	0.00488	CcSEcCtD
Pasireotide—Hypotension—Doxorubicin—muscle cancer	0.00157	0.00482	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—MDM2—muscle cancer	0.00157	0.00253	CbGpPWpGaD
Pasireotide—Abdominal pain—Methotrexate—muscle cancer	0.00153	0.00471	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00153	0.0047	CcSEcCtD
Pasireotide—Insomnia—Doxorubicin—muscle cancer	0.00152	0.00467	CcSEcCtD
Pasireotide—Decreased appetite—Doxorubicin—muscle cancer	0.00146	0.00449	CcSEcCtD
Pasireotide—Fatigue—Doxorubicin—muscle cancer	0.00145	0.00445	CcSEcCtD
Pasireotide—Constipation—Doxorubicin—muscle cancer	0.00144	0.00442	CcSEcCtD
Pasireotide—Asthenia—Methotrexate—muscle cancer	0.00139	0.00428	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—MDM2—muscle cancer	0.00139	0.00225	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00137	0.00422	CcSEcCtD
Pasireotide—Pruritus—Methotrexate—muscle cancer	0.00137	0.00422	CcSEcCtD
Pasireotide—Abdominal pain—Doxorubicin—muscle cancer	0.00133	0.00408	CcSEcCtD
Pasireotide—Diarrhoea—Methotrexate—muscle cancer	0.00133	0.00408	CcSEcCtD
Pasireotide—Dizziness—Methotrexate—muscle cancer	0.00128	0.00394	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—MDM2—muscle cancer	0.00128	0.00207	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—VEGFA—muscle cancer	0.00124	0.00201	CbGpPWpGaD
Pasireotide—Vomiting—Methotrexate—muscle cancer	0.00123	0.00379	CcSEcCtD
Pasireotide—Headache—Methotrexate—muscle cancer	0.00121	0.00374	CcSEcCtD
Pasireotide—Asthenia—Doxorubicin—muscle cancer	0.0012	0.0037	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—VEGFA—muscle cancer	0.00119	0.00192	CbGpPWpGaD
Pasireotide—Pruritus—Doxorubicin—muscle cancer	0.00119	0.00365	CcSEcCtD
Pasireotide—Nausea—Methotrexate—muscle cancer	0.00115	0.00354	CcSEcCtD
Pasireotide—Diarrhoea—Doxorubicin—muscle cancer	0.00115	0.00353	CcSEcCtD
Pasireotide—Dizziness—Doxorubicin—muscle cancer	0.00111	0.00341	CcSEcCtD
Pasireotide—Vomiting—Doxorubicin—muscle cancer	0.00107	0.00328	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—VEGFA—muscle cancer	0.00105	0.00171	CbGpPWpGaD
Pasireotide—Headache—Doxorubicin—muscle cancer	0.00105	0.00323	CcSEcCtD
Pasireotide—Nausea—Doxorubicin—muscle cancer	0.000997	0.00307	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—VEGFA—muscle cancer	0.000973	0.00157	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—TP53—muscle cancer	0.000937	0.00152	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—TP53—muscle cancer	0.000898	0.00145	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—TP53—muscle cancer	0.000797	0.00129	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—TP53—muscle cancer	0.000735	0.00119	CbGpPWpGaD
